Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.

Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.

Individualized predictions of disease progression following radiation therapy for prostate cancer.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.

Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.

Joint partially linear model for longitudinal data with informative drop-outs.

Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches

Choice of prognostic estimators in joint models by estimating differences of expected conditional Kullback-Leibler risks.

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.

Stochastic functional data analysis: a diffusion model-based approach.

Outcome of Patients with Localized Prostate Cancer Treated by Radiotherapy After Confirming the Absence of Lymph Node Invasion

Score test for conditional independence between longitudinal outcome and time to event given the classes in the joint latent class model.

The effect of salvage therapy on survival in a longitudinal study with treatment by indication.

Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of post-treatment PSA: a joint modelling approach

Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.

Individualized predictions of disease progression following radiation therapy for prostate cancer.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.

Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.

Joint partially linear model for longitudinal data with informative drop-outs.

Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches

Choice of prognostic estimators in joint models by estimating differences of expected conditional Kullback-Leibler risks.

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.

Stochastic functional data analysis: a diffusion model-based approach.

Outcome of Patients with Localized Prostate Cancer Treated by Radiotherapy After Confirming the Absence of Lymph Node Invasion

Score test for conditional independence between longitudinal outcome and time to event given the classes in the joint latent class model.

The effect of salvage therapy on survival in a longitudinal study with treatment by indication.

Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of post-treatment PSA: a joint modelling approach

Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.

Individualized predictions of disease progression following radiation therapy for prostate cancer.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.